AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's chief executive Pascal Soriot warned on Tuesday new U.S. legislation capping drug prices would reduce the ability of companies to recoup their investment on developing new drugs and hurt innovation.

AstraZeneca's Soriot warns new U.S. drug price law will hurt innovation

AstraZeneca is interested in acquiring small and mid-sized companies specialising in oncology and cardiovascular treatments, Chief Executive Pascal Soriot said in a Reuters Newsmaker interview on Tuesday.

AstraZeneca on hunt for oncology, cardiovascular acquisitions

Johnson & Johnson

Moderna

Pfizer

Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie

Ups & Downs: Top Pharmaceutical Stocks Post-COVID

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

Enhertu, AstraZeneca PLC (LSE:AZN)'s drug for women with HER2-positive breast cancer, delivered a statistically significant and clinically meaningful improvement in progression-free survival in the latest study. The DESTINY-Breast02 phase III trial pitted the AZ product against the doctors' own choice of treatment to assess efficacy.

AstraZeneca breast cancer drug performs well in latest trial

Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Significantly Delayed Disease Progression in DESTINY-Breast02 Versus Physician's Choice of Treatment in HER2 Positive Metastatic Breast Cancer

ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC (LSE:AZN) said its drug Enhertu has been given the green light in the US to be given to patients with advanced and difficult-to-treat non-small cell lung cancer. The Food & Drug Administration has approved the chemotherapy for use in people with inoperable tumours or where the cancer has spread beyond the lungs and the tumours have HER2 mutations.

AstraZeneca chemotherapy signed off for use in people with lung cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2m Metastatic Non-Small Cell Lung Cancer

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

AstraZeneca PLC (LSE:AZN) hailed as ‘transformational' a breast cancer treatment that has received fast-track sign-off by the US Food & Drug Administration. Enhertu, which AZ jointly developed with Japan's Daiichi Sankyo, has been approved for use in women with the HER-2 form of the disease where the tumour can't be operated on or where the cancer has spread.

AstraZeneca breast cancer drug gets the green light

AbbVie

Bristol-Myers

When the market is falling, this trio keeps rising.

3 Unstoppable Stocks That Don't Care About the Bear Market

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca (LSE/STO/Nasdaq: AZN) did not meet a pre-defined threshold for efficacy. Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. There were no new

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Cranking out new medicines is business as usual, but these three could be big earners.

Do These 3 New Moneymakers for AstraZeneca Make It a Buy?

These stocks share several things in common.

3 Stocks We Think Could Beat the Market in the Second Half of 2022

AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.

AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View

AstraZeneca raised its full-year sales guidance on strength from its Covid drugs, leading AZN stock to inch higher early Friday. The post AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments appeared first on Investor's Business Daily.

AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments

Long-serving AstraZeneca boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many years to come, suggesting he is not ready to retire.

AstraZeneca CEO Soriot says to work with new chairman for many years

AstraZeneca PLC (LSE:AZN) followed its smaller rival GSK PLC (LSE:GSK, NYSE:GSK) by upgrading guidance for the full year after a bumper first half which exceeded expectations. The key driver for the outperformance appears to be sales of the group's Covid vaccine, which was jointly developed with the University of Oxford.

AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience

AstraZeneca on Friday topped analyst expectations for second-quarter profit and revenue, helped by higher demand for its cancer medicines.

AstraZeneca beats Q2 profit and revenue estimates

Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.

Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?

AstraZeneca announced looming approval for two drugs in Europe and an FDA review for a third med, leading AZN stock to inch higher Monday. The post AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout appeared first on Investor's Business Daily.

AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout

AstraZeneca will announce Q222 earnings this Friday, July 29. The company has driven >90% share price growth over the past five years.

AstraZeneca: Q2 2022 Earnings May Not Wow Investors - Steady Growth's The Charm

AstraZeneca PLC (LSE:AZN) on Monday revealed why it is considered to have one of the strongest drug pipelines in the life sciences industry with three major announcements in the space of five minutes. In stock exchange missives the Anglo-Swedish giant said it had been granted a US priority review that would pave the way for the use of its treatment Enhertu in women with the HER-2 form of breast cancer.

News for AstraZeneca Stock (AZN)